Peter Leif Bergsagel MD

PubMed

• Dose Delays and Treatment Interruptions Secondary to Ocular Toxicity From BCMA-Directed Antibody Drug Conjugate Therapy in Relapsed Multiple Myeloma.
  Matthew J Rees, Timothy T Xu, Suheil Albert Atallah-Yunes, Kenneth J C Lim, Sikander Ailawadhi
  Clinical Lymphoma, Myeloma & Leukemia. 2025-10-05
• 3 citations
  Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma.
  Benjamin Diamond, Linda Baughn, Mansour Poorebrahim, Alexandra M Poos, Holly Lee
  Blood. 2025-09-25
• An immunostimulatory CELMoD combination overcomes resistance to T-cell engagers caused by a high multiple myeloma burden.
  Erin W Meermeier, Kirsten Pfeffer, Caleb K Stein, Meaghen Sharik, Megan Tien Du
  Blood. 2025-08-27

Journal Articles

• Inhibitors of the Protein Disulfide Isomerase Family for the Treatment of Multiple Myeloma  
  Peter Bergsagel, MD, Nature
• Utilization of Hematopoietic Stem Cell Transplantation for the Treatment of Multiple Myeloma: A Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consen...  
  John A Lust, Shaji K Kumar, Morie A Gertz, P Leif Bergsagel, Angela Dispenzieri, Francis K Buadi, Prashant Kapoor, Angela A Mayo, Wilson I Gonsalves, Rafael Fonseca, R..., Nature
• Immunosurveillance and therapy of multiple myeloma are CD226 dependent  
  Guillerey C, Ferrari de Andrade L, Vuckovic S, Miles K, Ngiow SF, Yong MC, Teng MW, Colonna M, Ritchie DS, Chesi M, Bergsagel PL, Hill GR, Smyth MJ, Martinet L, J Clin Invest, 1/1/2015
• Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth  
  Vallabhapurapu SD, Noothi SK, Pullum DA, Lawrie CH, Pallapati R, Potluri V, Kuntzen C, Khan S, Plas DR, Orlowski RZ, Chesi M, Kuehl WM, Bergsagel PL, Karin M, Vallabha..., Nature Communications, 1/1/2015
• Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells  
  Tanno T, Lim YT, Wang QJ, Chesi M, Bergsagel PL, Matthews G, Johnstone RW, Ghosh N, Borrello I, Huff CA, Matsui W, Blood, 1/30/2014
• Long-term follow-up of a phase 2 trial of single agent lenalidomide in previously untreated patients with chronic lymphocytic leukaemia  
  Chen CI, Paul H, Wang T, Le LW, Dave N, Kukreti V, Nong Wei E, Lau A, Bergsagel PL, Trudel S, Br J Haematol, 1/1/2014
• The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma  
  Munugalavadla V, Mariathasan S, Slaga D, Du C, Berry L, Del Rosario G, Yan Y, Boe M, Sun L, Friedman LS, Chesi M, Bergsagel PL, Ebens A, Oncogene, 1/1/2014
• Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia  
  Ghobrial IM, Witzig TE, Gertz M, Laplant B, Hayman S, Camoriano J, Lacy M, Bergsagel PL, Chuma S, Deangelo D, Treon SP, Am J Hematol, 1/1/2014
• Advances in Science, Emerging Data and Novel Therapeutics Highlights  
  Bergsagel PL, 51st Annual Hematology Meeting, 1/1/2010
• the Practicing Hematologist-Oncologist  
  Bergsagel PL, Mayo Clinic 7th Annual Hematology, 1/1/2010
• International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell...  
  Palumbo A, Sezer O, Kyle R, Miguel JS, Orlowski RZ, Moreau P, Niesvizky R, Morgan G, Comenzo R, Sonneveld P, Kumar S, Hajek R, Giralt S, Bringhen S, Anderson KC, Richa..., Leukemia, 1/1/2009
• International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple m...  
  Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, Kumar S, Munshi NC, Dispenzieri A, Kyle R, Merlini G, San Miguel J, Ludwig H, Hajek R, Jaga..., Leukemia, 1/1/2009
• International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Mye...  
  Dimopoulos M, Terpos E, Comenzo RL, Tosi P, Beksac M, Sezer O, Siegel D, Lokhorst H, Kumar S, Rajkumar SV, Niesvizky R, Moulopoulos LA, Durie BG, IMWG, Leukemia, 1/1/2009
• International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders  
  Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, Palumbo A, Jagannath S, Blade J, Lonial S, Dimopoulos M, Comenzo R, Einsele H, Barlogie B, Anderson K, ..., Leukemia, 1/1/2009
• Moffitt Advances in the Management of Multiple Myeloma  
  Bergsagel PL, 1/1/2009
• Reply to the research mission in myeloma by Richardson et al  
  Bergsagel PL, Leukemia, 1/7/2008
• Characterization of MYC translocations in multiple myeloma cell lines  
  Dib A, Gabrea A, Glebov OK, Bergsagel PL, Kuehl WM, Journal of the National Cancer Institute - Monographs, 1/1/2008
• The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement  
  Hussein MA, Vrionis FD, Allison R, Berenson J, Berven S, Erdem E, Giralt S, Jagannath S, Kyle RA, LeGrand S, Pflugmacher R, Raje N, Rajkumar SV, Randall RL, Roodman D,..., Leukemia, 1/1/2008
• The Multiple Myeloma SET Domain (MMSET) protein is a histone methyltransferase with characteristics of a transcriptional co-repressor  
  Marango J, Shimoyama M, Nishio H, Meyer JA, Min DJ, Sirulnik A, Martinez-Martinez Y, Chesi M, Bergsagel PL, Zhou MM, Waxman S, Leibovitch BA, Walsh MJ, Licht JD, Blood, 1/21/2007
• Survival of genetic subtypes of relapsed myeloma may be modulated by secondary events  
  Chng WJ, Mulligan G, Bryant B, Bergsagel L, Blood, 1/15/2007
• 2nd Genetics Multiple Myeloma  
  Bergsagel PL, Roundtable, 1/1/2006
• Malignant Lymphoma  
  Bergsagel PL, Ninth International Conference, 1/1/2005
• Early genetic events provide the basis for a clinical classification of multiple myeloma  
  Kuehl WM, Bergsagel PL, Hematology, 1/1/2005
• Multiple Myeloma 2004  
  Bergsagel PL, 1/1/2004
• Constipated myeloma  
  Bergsagel PL, Blood, 1/1/2004
• Join now to see all

Books/Book Chapters

• Wintrobe's clinical hematology 
  Chapter: Molecular genetic aspects of plasma cell disorders 
  Page 2022 - 2028Bergsagel PL, Stewart AK, Russell SJ, Morice WGEditors: Greer JP; et al.Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia, PAEdition 13th,2014
• Multiple myeloma: diagnosis and treatment 
  Chapter: Pathogenesis of multiple myeloma 
  Page 35 - 46Chesi M, Bergsagel PLEditors: Gertz MA; Rajkumar SV.Springer, New York, NY2014
• Neoplastic diseases of the blood 
  Chapter: Cytogenetic abnormalities in MGUS and myeloma 
  Page 589 - 599Fonseca R, Bergsagel PL, Kuehl WMEditors: Wiernik PH; et al.Springer, New York, NYEdition 5th,2013
• Molecular hematology 
  Chapter: The molecular biology of multiple myeloma 
  Page 127 - 139Chng WJ, Bergsagel PLEditors: Provan D; Gribben JG.Wiley-Blackwell, Chichester, UK; Hoboken, NJ2010
• Treatment of multiple myeloma and related disorders 
  Chapter: Diagnosis and genetic classification of multiple myeloma 
  Page 1 - 17Fonseca R, Bergsagel PLEditors: Rajkumar SV, Kyle RA.Cambridge University Press, Cambridge, UK; New York, NY2009
• Myeloma therapy: pursuing the plasma cell 
  Chapter: Biology-based classification and staging of multiple myeloma 
  Page 41 - 56Chng WJ, Bergsagel PLEditors: Lonial S.Humana, Totowa,NJ2008
• Multiple Myeloma 
  Chapter: Epidemiology and Etiology of Multiple Myeloma 
  Bergsagel DE, Bergsagel PLEditors: Gharton G, Durie B, Samson D.Arnold, London, UK; New York, NYEdition 2nd,2003
• Biology and Therapy of Multiple Myeloma 
  Chapter: Epidemiology and Pathogenesis of Multiple Myeloma 
  Bergsagel PLEditors: Richardson P, Anderson KC.Remedica, London, UK2003
• Neoplastic diseases of the blood 
  Chapter: Cytogenetic abnormalities in the monoclonal gammopathies 
  Page 470 - 476Fonseca R, Bergsagel PL, Kuehl WMEditors: Wiernik PH, Goldman JM, Dutcher JP, Kyle RA.Cambridge University Press, Cambridge, UKEdition 4th,2003
• Myeloma: biology and management 
  Chapter: Molecular pathogenesis of multiple myeloma 
  Page 48 - 69Bergsagel PL, Kuehl WMEditors: Malpas J, Bergsagel DE, Anderson KC, Kyle RA.Oxford University Press, Oxford, UKEdition 2nd,1998
• Join now to see all

Abstracts/Posters

• Interim analysis of a phase ii trial of nab-paclitaxel in patients with very advanced relapsed/refractory multiple myeloma (rr-mm)
  Rosenthal AC, Fonseca R, Mikhael J, Stewart AK, Mayo A, Chesi M, Kosiorek H, Bergsagel PL, J Clin Oncol, 1/20/2015
• Uch-l1 synergizes with bcl6 and predicts a poor outcome in diffuse large b-cell lymphoma
  Bedekovics T, Hussain S, Feldman AL, Chesi M, Bergsagel PL, Galardy PJ, Br J Haematol, 1/1/2015
• Targeting genetic heterogeneity in multiple myeloma through immune activation
  Chesi M, Bergsagel PL, Clin Cancer Res, 1/1/2015
• Angiogenesis associated with alterations of the bone marrow microenvironment predicts multiple myeloma progression to symptomatic disease in mice and humans
  Calcinotto A, Ponzoni M, Ria R, Grioni M, Cattaneo E, Villa I, Bertilaccio MTS, Chesi M, Rubinacci A, Tonon G, Bergsagel PL, Vacca A, Bellone M, Blood, 1/6/2014
• Development and results of a multiple myeloma specific custom 77-gene mutation panel for clinical targeted sequencing
  Kortuem KM, Stewart AK, Bruins LA, Ahmann G, Vasmatzis G, Rajkumar SV, Kumar S, Blood, 1/6/2014
• Pomalidomide plus low-dose dexamethasone (pom/dex) in relapsed lenalidomide refractory myeloma: long term follow up and comparison of 2 mg vs 4 mg doses
  Lacy MQ, LaPlant BR, Laumann KM, Kumar S, Gertz MA, Hayman SR, Buadi F, Dispenzieri A, Lust JA, Kapoor P, Leung N, Russell S, Dingli D, Go RS, Gonsalves WI, Fonseca R,..., Blood, 1/6/2014
• Pomalidomide, bortezomib and dexamethasone (pvd) for patients with relapsed lenalidomide refractory multiple myeloma (mm)
  Lacy MQ, LaPlant BR, Laumann KM, Kumar S, Gertz MA, Hayman SR, Buadi F, Dispenzieri A, Lust JA, Kapoor P, Leung N, Russell SJ, Dingli D, Gonsalves WI, Fonseca R, Bergs..., Blood, 1/6/2014
• Identification of novel therapeutic targets in the clinically predictive vk myc mouse model of multiple myeloma
  Chesi M, Garbitt V, Bergsagel PL, Blood, 1/6/2014
• Early trafficking of bone marrow derived-endothelial progenitor cells promotes multiple myeloma progression
  Moschetta M, Mishima Y, Kawano Y, Aljawai Y, Paiva B, Palomera L, Calcinotto A, Christine UL, Sahin I, Sacco A, Glavey S, Reagan MR, Manier S, Bergsagel PL, Chesi M, B..., Blood, 1/6/2014
• The cardiovascular impact of carfilzomib in multiple myeloma
  Rosenthal AC, Luthi J, Belohlavek M, Mookadam F, Mayo A, Fonseca R, Bergsagel PL, Reeder CB, Mikhael JR, Stewart K, Blood, 1/6/2014
• A Phase II clinical trial of rituximab cyclophosphamide, bortezomig, and dexamethasone (R-CyBor-D) in relapsed low grade and mantle cell lymphoma
  Rosenthal AC, Dueck AC, Gano K, Nichols C, Johnson D, Toro A, Reddy SN, Slack JL, Leis JF, Northfelt DW, Bergsagel PL, Tiedemann R, Johnston PB, Habermann TM, Witzig T..., Blood, 1/1/2014
• Asimakopoulos F. Tpl2 kinase regulates the inflammatory milieu of the myeloma niche
  Hope C, Ollar SJ, Heninger E, Jensen JL, Hebron E, Kim J, Maroulakou I, Miyamoto S, Callander N, Hematti P, Chesi M, Bergsagel PL, Asimakopoulos F, Cancer Res, 1/1/2014
• Targeting myc in multiple myeloma by bet protein inhibition
  Riggs DL, Chesi M, Bergsagel PL, Cancer Res, 1/1/2014
• Cb-5083, a first in class inhibitor of the aaa-atpase p97ncp, induces irresolvable er stress that results in antitumor activity in solid and hematological tumor models
  Yakes F, Le Moigne R, Wong S, Anderson DJ, Djakovic S, Valle E, Menon MK, Rice J, Yao B, Soriano F, Wang J, von Soly SK, Chesi M, Bergsagel PL, Zhou HJ, Rolfe M, Wustr..., Eur J Cancer, 1/1/2014
• Promiscuous cryptic rearrangements of the myc locus cis-dysregulate myc expression and are present in the majority of patients with hyperdiploid myeloma
  Bergsagel PL, Affer M, Glebov OK, Chen WDD, Keats JJ, Brents LA, Chesi M, Van Wier S, Badar SK, Fonseca R, Kuehl WM, Blood, 1/16/2012
• Long-term follow-up of a phase 2 study of single agent lenalidomide in previously untreated, symptomatic chronic lymphocytic leukemia (cll)
  Chen C, Paul H, Wang T, Le LW, Kukreti V, Wei EN, Lau A, Bergsagel PL, Dave N, Trudel S, Blood, 1/16/2012
• Pomalidomide plus low-dose dexamethasone (POM/DX) in relapsed myeloma: long term follow up and factors predicing outcome in 345 patients
  Lacy MQ, Kumar SK, LaPlant BR, Laumann K, Gertz MA, Hayman SR, Buadi FK, Dispenzieri A, Lust JA, Russell S, Dingli D, Zeldenrust SR, Fonseca R, Bergsagel PL, Stewart K..., Blood, 1/16/2012
• Results from the phase ii dose expansion of cyclophosphamide, carfilzomib, thalidomide and dexamethasone (cyclone) in patients with newly diagnosed multiple myeloma
  Mikhael JR, Reeder CB, Libby EN III, Costa LJ, Bergsagel PL, Buadi F, Mayo A, Gano K, Wolf C, Dueck AC, Stewart AK, Blood, 1/16/2012
• Phase ii trial of intravenously administered amd3100 (plerixafor) for stem cell mobilization in patients with multiple myeloma undergoing autologous stem cell transpla...
  Kumar S, Mikhael J, Lacy M, LaPlant B, Buadi F, Dingli D, Gertz M, Miceli T, Bergsagel L, Hayman S, Reeder C, Stewart K, Dispenzieri A, Gastineau D, Winters J, Biol Blood Marrow Transplant, 1/1/2012
• A CD28 based bi-directional molecular bridge that support plasma cell survival in the bone marrow
  Nair J, Murray M, Koorella C, Rozanski C, Carlson L, Shaughnessy J, Bergsagel P, Boise L, Lee K, J Immunol, 1/1/2012
• Generation of an automated tool for the identification of genetics markers and signatures in multiple myeloma risk-stratification
  Braggio E, Keats JJ, Kumar S, Ahmann G, Mantei J, Stewart K, Bergsagel PL, Fonseca R, Blood, 1/19/2011
• Long term outcomes of pomalidomide and dexamethasone in patients with relapsed multiple myeloma: analysis 4 years after the original cohort
  Mikhael JR, Hayman SR, Laumann K, Roy V, LaPlant BR, Kumar S, Buadi FK, Reeder CB, Gertz MA, Dispenzieri A, Lust JA, Stewart AK, Russell S, Bergsagel PL, Dingli D, Zel..., Blood, 1/18/2011
• Phase II trial of intravenously administered AMD3100 (plerixafor) for stem cell mobilization in patients with multiple myeloma undergoing autologous stem cell transpla...
  Kumar S, Mikhael JR, Lacy MQ, LaPlant BR, Buadi FK, Dingli D, Gertz MA, Miceli T, Mahlman M, Bergsagel PL, Hayman SR, Reeder CB, Dispenzieri A, Gastineau DA, Winters J, Blood, 1/18/2011
• Pomalidomide and dexamethasone in relapsed myeloma: results of 225 patients treated in five cohorts over three years
  Lacy MQ, LaPlant BR, Laumann K, Gertz MA, Hayman SR, Buadi FK, Dispenzieri A, Kumar S, Lust JA, Russell S, Dingli D, Zeldenrust SR, Greipp PR, Fonseca R, Bergsagel PL,..., Blood, 1/18/2011
• Inhibition of c-myc expression and function in hematologic malignancies
  Issa GC, Delmore JE, McKeown MR, Lemieux ME, Rahl PB, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, Shi JW, Chesi M, Schinzel AC, Vakoc CR, Bergsagel PL, Ric..., Blood, 1/18/2011
• Join now to see all

Lectures

• A Single-Cell Transcriptional Analysis of Tumour Cells and the Immune Microenvironment during Disease Evolution in a Transgenic Mouse Model of Myeloma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018